Hosted on MSN

FBLG: Phase 1/2 trial of CYWC628 underway

On June 3, 2026, FibroBiologics, Inc. (NASDAQ: FBLG) announced that the first patients have been dosed in the Phase 1/2 trial of CYWC628, the company’s allogenic fibroblast cell therapy that is being ...
Nature

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

AE of special interest (AESI) were secondary safety endpoints, and included ocular events, thrombocytopenia, infusion-related reactions, and ocular findings on ophthalmic exam. Ocular event ...